Terns Pharmaceuticals

130 articles about Terns Pharmaceuticals

• Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

  4/10/2024

  Terns Pharmaceuticals, Inc. announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.

• Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

  3/14/2024

  Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided corporate updates.

• Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

  3/11/2024

  Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).

• Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

  3/7/2024

  Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, announced that it has granted as of March 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended.

• Terns Pharmaceuticals to Participate in Upcoming March 2024 Investor Conferences

  2/27/2024

  Terns Pharmaceuticals, Inc. announced that members of senior management will be participating in the following upcoming investor conferences in March.

• Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)

  2/7/2024

  Terns Pharmaceuticals, Inc. announced that it has granted effective as of March 1, 2024 equity inducement awards to Amy Burroughs, the Company’s new Chief Executive Officer, under the terms of the 2022 Employment Inducement Award Plan, as amended.

• Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive OfficerProven Industry Executive Brings More Than 25 Years of Leadership Experience

  2/7/2024

  Terns Pharmaceuticals, Inc. today announced the appointment of Amy Burroughs as chief executive officer (CEO), effective immediately.

• Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - February 02, 2024

  2/2/2024

  Terns Pharmaceuticals, Inc. announced that it has granted as of February 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended.

• Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

  1/4/2024

  Terns Pharmaceuticals, Inc. announced that management will provide an update on its pipeline and strategic priorities for 2024 during the Company’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 10th, 2024 at 1:30pm PT.

• Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Jan 03, 2024

  1/3/2024

  Terns Pharmaceuticals, Inc. announced that it has granted as of January 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended.

• Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

  11/29/2023

  Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit.

• Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

  11/27/2023

  Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, announced that Senthil Sundaram, the Company’s recently retired Chief Executive Officer, passed away on November 22, 2023, following his battle with cancer.

• Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

  11/14/2023

  Terns Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023 and provided corporate updates.

• Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

  11/13/2023

  Terns Pharmaceuticals, Inc. announced the late-breaking oral presentation of top-line data from its Phase 2a DUET clinical trial of TERN-501, an investigational orally administered thyroid hormone receptor-β agonist for the treatment of NASH.

• Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

  11/9/2023

  Terns Pharmaceuticals, Inc. today announced that members of management will be participating in the following upcoming investor conferences in November.

• Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - November 03, 2023

  11/3/2023

  Terns Pharmaceuticals, Inc. announced that it has granted as of November 1, 2023 equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan, as amended.

• Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

  11/2/2023

  Terns Pharmaceuticals, Inc. today announced that the first participant has been dosed in the Phase 1 clinical trial of TERN-601, the Company’s oral small-molecule glucagon-like peptide-1 receptor, or GLP-1R, agonist for the treatment of obesity.

• Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

  10/19/2023

  Terns Pharmaceuticals, Inc. announced that members of management will be participating in the following upcoming investor conferences.

• Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

  10/16/2023

  Terns Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration’s (FDA’s) clearance of the Company’s Investigational New Drug application and the design of the CARDINAL Trial, Terns’ global Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of TERN-701 in participants with chronic myeloid leukemia (CML).

• Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - October 03, 2023

  10/3/2023

  Terns Pharmaceuticals, Inc. announced that it has granted as of October 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.